BIO-RAD LABORATORIES INC

For the period ended Dec 31, 2023. Filed Feb 16, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 16, 2024

BIO$386.48-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at

(In thousands, except share data)

	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$403,815	$434,215
Short-term investments	1,203,327	1,356,457
Restricted investments	5,560	5,560
Accounts receivable, less allowance for credit losses of $14,926 and $15,029 as of December 31, 2023 and 2022, respectively	489,017	494,645
Inventory	780,517	719,316
Prepaid expenses	140,040	124,179
Other current assets	26,054	23,604
Total current assets	3,048,330	3,157,976
Property, plant and equipment, net	529,007	498,612
Operating lease right-of-use assets	194,730	180,952
Goodwill, net	413,569	406,488
Purchased intangibles, net	320,514	332,147
Other investments	7,698,070	8,830,892
Other assets	94,850	94,599
Total assets	$12,299,070	$13,501,666

(continued)

(In thousands, except share data)

	December 31,
	2023	2022
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$144,625	$135,041
Accrued payroll and employee benefits	139,929	194,790
Current maturities of long-term debt and notes payable	486	465
Income and other taxes payable	35,759	32,428
Current operating lease liabilities	40,379	36,336
Other current liabilities	161,621	169,648
Total current liabilities	522,799	568,708
Long-term debt, net of current maturities	1,199,052	1,197,716
Deferred income taxes	1,475,495	1,770,481
Operating lease liabilities	165,478	153,597
Other long-term liabilities	195,113	195,912
Total liabilities	3,557,937	3,886,414
Commitments and contingent liabilities
Stockholders’ equity:
Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,169,944 and 25,162,075 at 2023 and 2022, respectively; shares outstanding - 23,422,506 and 24,521,583 at 2023 and 2022, respectively	2	2
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,095,930 and 5,074,130 at 2023 and 2022, respectively	1	1
Additional paid-in capital	449,075	447,454
Class A treasury stock at cost, 1,747,438 shares at 2023 and 640,492 shares at 2022	(632,536)	(263,586)
Retained earnings	9,260,629	9,898,203
Accumulated other comprehensive loss	(336,038)	(466,822)
Total stockholders’ equity	8,741,133	9,615,252
Total liabilities and stockholders’ equity	$12,299,070	$13,501,666

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.